An Open-label Parallel Arm Multiple Dose Tolerability, Pharmacokinetics and Safety Study in Adult Patients With Schizophrenia Following Administration of Aripiprazole IM Depot Formulation Once Every Four Weeks
Latest Information Update: 07 Nov 2021
At a glance
- Drugs Aripiprazole (Primary)
- Indications Schizophrenia
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Otsuka Pharmaceutical Development & Commercialization
- 27 Jun 2013 New trial record